Prostate Cancer - Results from #720

Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]. June 21, 2024

Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial. June 21, 2024

Impact of Mental Health Illness Prior to Prostate Cancer Diagnosis on Treatment Received and Prostate Cancer Outcomes June 20, 2024

Germline Gene-Specific Associations in a Large Prostate Cancer Cohort June 20, 2024

Informed Decision-Making About Germline Testing Among Veterans with Advanced Prostate Cancer: A Mixed-Methods Study June 20, 2024

Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. June 20, 2024

Transition-zone PSA-density calculated from MRI deep learning prostate zonal segmentation model for prediction of clinically significant prostate cancer. June 20, 2024

Machine Learning to Predict Prostate Artery Embolization Outcomes. June 20, 2024

Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineages. June 19, 2024

The Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients Shows the Importance of Estrogens in Males. June 19, 2024

Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN). June 19, 2024

TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations. June 19, 2024

Estimating the Effect of Radical Prostatectomy: Combining Data From the SPCG4 and PIVOT Randomized Trials With Contemporary Cohorts. June 19, 2024

Statistical analysis plan for the TRANSLATE (TRANSrectal biopsy versus Local Anaesthetic Transperineal biopsy Evaluation of potentially clinically significant prostate cancer) multicentre randomised controlled trial. June 19, 2024

Identifying proteomic risk factors for overall, aggressive, and early onset prostate cancer using Mendelian Randomisation and tumour spatial transcriptomics. June 18, 2024

Insulin resistance during androgen deprivation therapy in men with prostate cancer. June 18, 2024

Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. June 18, 2024

Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in Oncology. June 18, 2024

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update. June 18, 2024

Patient Perceptions of Standardized Risk Language Used in American College of Radiology Prostate MRI PIRADS Scores. June 18, 2024

Page 37 of 1436